Monthly Archives: August, 2010
Alexza’s Staccato® Nicotine Licensed to Cypress Bioscience
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq:CYPB – News). The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by [...]
FDA panel rejects Jazz drug
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) U.S. advisory panel on Friday rejected a Jazz Pharmaceuticals Inc (JAZZ.O) Nasdaqmedicine to treat the pain disorder fibromyalgia amid concerns the product could be misused as a “date-rape” drug. A Food and Drug Administration advisory committee voted 20-2 against recommending approval of sodium oxybate or JZP-6. The medicine contains a [...]
RPRX has received positive written feedback from the FDA
Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received positive written feedback from the FDA (the “Agency”) regarding the Company’s drug candidate Androxal®. The Agency concurred with Repros’ indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility. In the written advice letter the [...]
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference. The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET. The presentation will be webcast from the Southampton [...]
RPRX Back in Play
Penny stock picks gave the heads up on RPRX in June on Proellex lift, and now there could be a chance to make more money on this penny stock play with Androxal. And we have are adding this to our radar on FDA news for Androxal. RPRX : (Nasdaq) Are awaiting response from the FDA [...]
ARNA Arena Pharma stock offering
Arena Pharmaceuticals Inc. said Friday it expects to receive about $60 million before expenses from a direct public offering of stock to entities tied to the health investment firm Deerfield Management. Arena, which is based in San Diego, said it will sell a total of about 8.9 million shares for $6.70 per share. The offering [...]
Penny Stock Pick Feature ALXA Alexza Pharmaceuticals, Inc.
We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with the upcoming FDA meeting in October for AZ-004 Staccato loxapine, we ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big [...]
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) AEZS a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the National Institutes of Health (“NIH”) has awarded Dr. Jacek Pinski, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, a grant of about US $ [...]
Arena JPMorgan downgrade
Shares of Arena Pharmaceuticals Inc. fell Monday after a JPMorgan analyst recommended a cautious stance on the stock, citing the near-term risks compared with the rewards for the obesity drug lorcaserin. THE SPARK: Analyst Cory Kasimov downgraded shares to “Neutral” from “Overweight” citing the stock’s jump following a Food and Drug Administration panel recommendation for [...]